Mexico is one of LatinAmerica countries with the highest prevalence (14.4%) of DM. Medical institutions face the challenge to provide medical care to T2DM patients that failed to several antidiabetic regimens. We conducted a retrospective study to assess the response to dapagliflozin (Dapa) or DPP-4-inhibitors (DPP-4i) as added-on therapy in T2DM patients with failure to previous medications.

Objectives: Compare subjects with ≥5% improvement of the weighted sum of the three variables of the composite variable (HbA1c plus body weight (BW) plus blood pressure (BP) by the end of the 74-week observation period from index date) and proportion of patient achieving HBA1c of 7%.

Inclusion Criteria: T2DM subjects ≥18 years old with failure to any previous antidiabetic medication and HbA1c% ≥7 that started Dapa or DPP-4i as add-on to other antidiabetic drugs from August 2014 to Jun 2018.

Statistical Methods and Analysis: A propensity score matching model (nearest neighbor algorithm) was used, covariates included were treatment regimen, TC, LDL-c, HbA1c, BW, systolic BP and age.

Results: Of 1800 subjects, 221 met statistical matching criteria. No differences in basal characteristics of age, SBP, CrCl, but DAPA group had higher basal HbA1c (8.68±1.59 vs. 8.19±1.4, p<0.01). Dapa group had a significant improvement (>5%) in the composite variable compared to DPP-4i at 24 (76.9% vs. 46%, p<0.01), 52 (82.4% vs. 49.5%, p<0.01) and 76 weeks(84.6% vs. 39.2%, p<0.01). Patients with HbA1c goal of <7% in Dapa group compared to iDPP-4 at 24 (44.3% vs. 29.9%, p<0.01), 52 (48.9% vs. 29.1%, p<0.01) and 76 weeks (51.9% vs. 21.8%, p<0.01).

Conclusion: In patients with uncontrolled T2DM who have failed to previous antidiabetic therapies, the add-on of dapagliflozin significantly provides reductions of HbA1c, glucose, weight and blood with more patients achieving glucose control goals compared to iDPP-4.


D. Espinoza-Peralta: None. A. González-Cantú: None. A.I. Silva: Employee; Self; AstraZeneca. J.G. Collado: None. J. Rogel-Manzanares: None. J.H. Hernández-Alarcón: None. A.G. Noriega-Muñoz: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at